Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 6;6(13):3921–3931. doi: 10.1182/bloodadvances.2022007359

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

PMC Copyright notice

Figure 3. — Overall survival by Kaplan-Meier analysis of lower-risk patients according to CPSS, CPSS-P, and Mayo-prognostic model. (A) OS analysis. Patients with OM-CMML had a significantly longer OS than did those with D-CMML (median OS, 131.81 vs 62.36 months; P = .038) and P-CMML (median OS, 131.81 vs 41.46; P = .001). (B) OS by Kaplan-Meier analysis of lower-risk patients by CPSS-P. Patients with OM-CMML did not have a significantly longer OS than did those with D-CMML (median OS: 131.81 vs 74.65 months; P = .199), but presented a significantly longer OS than did those with P-CMML (median OS, 131.81 vs 45.04; P = .005). (C) OS by Kaplan-Meier analysis of lower-risk patients by the Mayo prognostic model. Patients with OM-CMML had a significantly longer OS than did those with D-CMML (median OS, 131.81 vs 62.36 months; P = .046) and P-CMML (median OS, 131.81 vs 38.4; P < .001). OS was compared with 2-sided log-rank tests.